Drugs / [212Pb]Pb-PSV359
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06710756 | Apr 2025 → Jan 2028 expected | colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer +4 | Perspective Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-21 | Perspective Therapeutics | Results Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma perspectivetherapeutics.com ↗
initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-21 | Perspective Therapeutics | Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma perspectivetherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [212Pb]Pb-PSV359 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06710756 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT06710756 ↗ |